BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15994736)

  • 1. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 2. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life switching strategies with second-generation antipsychotics.
    Correll CU
    J Clin Psychiatry; 2006 Jan; 67(1):160-1. PubMed ID: 16426102
    [No Abstract]   [Full Text] [Related]  

  • 5. Methodological issues in a comparative study of ziprasidone and risperidone.
    Gharabawi GM; Bossie CA; Mahmoud R; Canuso CM; Lasser RA; Turkoz I; Greenspan A
    J Clin Psychiatry; 2006 Jan; 67(1):162-3; author reply 163-4. PubMed ID: 16426103
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical experiences and clinical trials.
    Fusar-Poli RR
    CNS Spectr; 2008 Jun; 13(6):461-2; author reply 462-3. PubMed ID: 18567969
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziprasidone and mania.
    Ross DE
    Am J Psychiatry; 2004 Aug; 161(8):1503. PubMed ID: 15285991
    [No Abstract]   [Full Text] [Related]  

  • 8. Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.
    Margetic B; Aukst-Margetic B
    World J Biol Psychiatry; 2007; 8(2):131-2; author reply 133-4. PubMed ID: 17455107
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
    Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
    Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
    Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
    Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
    Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
    J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
    Li YM; Zhao JP; Ou JJ; Wu RR
    Pharmacopsychiatry; 2012 Jul; 45(5):177-81. PubMed ID: 22290206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone augmentation of clozapine in 11 patients.
    Kaye NS
    J Clin Psychiatry; 2003 Feb; 64(2):215-6. PubMed ID: 12633133
    [No Abstract]   [Full Text] [Related]  

  • 17. Ziprasidone hydrochloride.
    Am J Health Syst Pharm; 2002 Jan; 59(1):28-9. PubMed ID: 11813463
    [No Abstract]   [Full Text] [Related]  

  • 18. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
    Thone J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):481-2. PubMed ID: 18070865
    [No Abstract]   [Full Text] [Related]  

  • 20. Aripirazole-olanzapine combination for treatment of schizophrenia.
    Duggal HS
    Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.